目的:调查2017-2022年美国(AoU)研究计划中他汀类药物使用与青光眼之间的关系。
方法:横截面,以人口为基础。
方法:79,742名年龄≥40岁的高脂血症患者和AoU数据库中的电子健康记录(EHR)数据。
方法:高脂血症,青光眼状态,根据AoU收集的EHR数据中的诊断和用药信息来定义他汀类药物的使用.进行Logistic回归分析以评估他汀类药物使用与青光眼可能性之间的相关性。使用Logistic回归模型来检查青光眼与调整分析中包含的所有协变量之间的关联。使用血清低密度脂蛋白胆固醇(LDL-C)评估高脂血症的严重程度。按LDL-C水平和年龄进行分层分析。
方法:在EHR数据中发现的由国际疾病分类(ICD)代码定义的任何青光眼。
结果:在AoU的79,742名高脂血症患者中,有6,365名(8.0%)他汀类药物使用者.与不使用他汀类药物相比,使用他汀类药物与青光眼患病率增加相关(校正比值比[aOR]:1.13,95%置信区间[CI]:1.01-1.26)。较高的LDL-C血清水平与青光眼几率增加相关(aOR:1.003,95%CI:1.003,1.004)。他汀类药物使用者的LDL-C水平明显高于非使用者(144.9mg/dL对136.3mg/dL,p值<0.001)。LDL-C分层分析发现,在LDL-C水平最佳(aOR=1.39,95%CI=1.05-1.82)和较高(aOR=1.37,95%CI=1.09-1.70)的患者中,他汀类药物的使用与青光眼患病率之间存在正相关。年龄分层分析显示,在60-69岁的个体中,他汀类药物的使用与青光眼患病率之间存在正相关(aOR=1.28,95%CI=1.05-1.56)。
结论:他汀类药物的使用与合并高脂血症的成人AoU人群青光眼的可能性增加有关,在具有最佳或高LDL-C水平的个体中,以及60-69岁的人。研究结果表明,他汀类药物的使用可能是青光眼的独立危险因素,这可能进一步受到一个人的血脂和年龄的影响。
OBJECTIVE: To investigate associations between statin use and glaucoma in the 2017-2022 All of Us (AoU) Research Program.
METHODS: Cross-sectional, population-based.
METHODS: 79,742 adult participants aged ≥ 40 years with hyperlipidemia and with electronic health record (EHR) data in the AoU database.
METHODS: Hyperlipidemia, glaucoma status, and statin use were defined by diagnoses and medication information in EHR data collected by AoU. Logistic regression analysis was performed to evaluate the association between statin use and glaucoma likelihood. Logistic regression modeling was used to examine associations between glaucoma and all covariates included in adjusted analysis. Serum low-density lipoprotein cholesterol (LDL-C) was used to assess hyperlipidemia severity. Analyses stratified by LDL-C level and age were performed.
METHODS: Any glaucoma as defined by International Classification of Diseases (ICD) codes found in EHR data.
RESULTS: Of 79,742 individuals with hyperlipidemia in AoU, there were 6,365 (8.0%) statin users. Statin use was associated with increased glaucoma prevalence when compared with statin non-use (adjusted odds ratio [aOR]: 1.13, 95% confidence interval [CI]: 1.01-1.26). Higher serum levels of LDL-C were associated with increased odds of glaucoma (aOR: 1.003, 95% CI: 1.003, 1.004). Statin users had significantly higher LDL-C levels compared to nonusers (144.9 mg/dL versus 136.3 mg/dL, p-value < 0.001). Analysis stratified by LDL-C identified positive associations between statin use and prevalence of glaucoma among those with optimal (aOR = 1.39, 95% CI = 1.05-1.82) and high (aOR = 1.37, 95% CI = 1.09-1.70) LDL-C levels. Age-stratified analysis showed a positive association between statin use and prevalence of glaucoma in individuals aged 60-69 years (aOR = 1.28, 95% CI = 1.05-1.56).
CONCLUSIONS: Statin use was associated with increased glaucoma likelihood in the overall adult AoU population with hyperlipidemia, in individuals with optimal or high LDL-C levels, and in individuals 60-69 years old. Findings suggest that statin use may be an independent risk factor for glaucoma, which may furthermore be affected by one\'s lipid profile and age.